| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| 2seventy bio Inc. | Abecma (idecabtagene vicleucel) - (KarMMa-2) | Newly diagnosed multiple myeloma | Phase 2 | Ongoing | Intravenous | Oncology |
| 2seventy bio Inc. | Abecma (idecabtagene vicleucel) - (KarMMa-9) | Newly Diagnosed Multiple Myeloma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| 3M Company | EscharEx - (VALUE) | Venous leg ulcers (VLU’s) | Phase 3 | Ongoing | Topical | Wound Care |
| 4D Molecular Therapeutics Inc. | 4D-150 - (4FRONT-2) | wet AMD | Phase 3 | Trial Planned | intravitreal | Opthalmic |
| 4D Molecular Therapeutics Inc. | 4D-150 - (SPECTRA) | Wet Age-Related Macular Degeneration (wet AMD) | Phase 3 | Data Released | Intravitreal | Opthalmic |
| 4D Molecular Therapeutics Inc. | 4D-150 - (PRISM) | Wet age-related macular degeneration (AMD) | Phase 2b | Data Released | Intravitreal injection | Opthalmic |
| 4D pharma plc | Blautix (MRx1234) | Irritable bowel syndrome (IBS) | Phase 2 | Oral | Gastroenterology | |
| 4D pharma plc | MRx0518 with bavencio (avelumab) | 1L Urothelial carcinoma | Phase 2 | Intravenous | Oncology |